Fapon Introduces One-Stop Chemiluminescence Immunoassay Solution at MEDICA 2022

(Dongguan, China) is displaying its extensive IVD product portfolio at MEDICA 2022 comprising of core IVD raw materials for immunoassays and molecular diagnostics, including 1300+ antibodies, antigens, enzymes, blockers, etc.; reagent services for comprehensive disease testing; open instrument platforms for chemiluminescence Immunoassay (CLIA) and molecular diagnostics; and its one-stop solution for CLIA.

At this year’s edition of MEDICA, Fapon is exhibiting the Shine i1000 fully automatic and simple-to-use benchtop CLIA analyzer which has a throughput of 120 tests per hour and provides the first result in less than 15 minutes. Shine i1000 combines incubation, washing and detection in an all-in-one innovative design and its small size with a weight of less than 38 kg makes it ideal for different settings. Fapon is also displaying the Shine i2000 fully automatic CLIA analyzer which has a throughput of up to 200 tests per hour and takes 10-15 minutes to deliver the first result. Shine i2000 has a built-in 10-12 point calibration curve with 2-3 point verification and offers convenience with a three hour walk away capacity.

Alongside the CLIA analyzers, Fapon’s rapid molecular diagnostic systems, the P810 and iCatch 2000, are also on display at MEDICA 2022. The P810 is a real-time fluorescence quantitative PCR analyzer that is designed for scientific research and medical applications which integrates nucleic acid amplification, result analysis and report delivery. iCatch 2000 is a fully automatic nucleic acid analyzer which can realize sample-to-answer automation within 30 minutes. In addition, is highlighting its raw materials and reagent solutions for both immunoassay and molecular diagnostics platforms, such as cardiac markers, tumor markers, respiratory disease, inflammatory markers, tropical diseases, infectious diseases, drug of abuse, polymerase & mix, reverse transcriptase & mix, LAMP polymerase, etc.

Related Links:
Fapon Biotech Inc.